Sales to Customers | Long-Lived Assets (6) | |||||||||||||||||||
(Dollars in Millions) | 2013 | 2012 | 2011 | 2013 | 2012 | 2011 | ||||||||||||||
United States | $ | 31,910 | 29,830 | 28,908 | $ | 35,880 | 35,115 | 23,529 | ||||||||||||
Europe | 18,599 | 16,945 | 17,129 | 24,868 | 25,261 | 19,056 | ||||||||||||||
Western Hemisphere excluding U.S. | 7,421 | 7,207 | 6,418 | 3,281 | 3,636 | 3,517 | ||||||||||||||
Asia-Pacific, Africa | 13,382 | 13,242 | 12,575 | 2,434 | 2,362 | 2,163 | ||||||||||||||
Segments total | 71,312 | 67,224 | 65,030 | 66,463 | 66,374 | 48,265 | ||||||||||||||
General corporate | 992 | 899 | 750 | |||||||||||||||||
Other non long-lived assets | 65,228 | 54,074 | 64,629 | |||||||||||||||||
Worldwide total | $ | 71,312 | 67,224 | 65,030 | $ | 132,683 | 121,347 | 113,644 |
(1) | Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively. |
(2) | General corporate includes cash and marketable securities. |
(3) | Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Diagnostics and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively. |
(4) | Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program. |
(5) | Includes $3,310 million of net litigation expense comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical segment. The Medical Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip program. |
(6) | Long-lived assets include property, plant and equipment, net for 2013, 2012 and 2011 of $16,710, $16,097 and $14,739, respectively, and intangible assets and goodwill, net for 2013, 2012 and 2011 of $50,745, $51,176 and $34,276, respectively. |